Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|September 3, 2009

Chiltern Develops Functional Service Model Relationships in Western Europe

London, UK-September 3, 2009

Chiltern International Limited, a global clinical research organization (CRO) has been selected as the sole provider of clinical research staff for the monitoring aspect of all clinical research projects for Western Europe for a top pharmaceutical company.

All CRAs will be seconded via Chiltern’s European Resourcing Solutions team and fully allocated to the company under a Functional Service or FSP model. The Chiltern CRAs will work directly with the client Project Managers.

Another leading pharmaceutical company also selected Chiltern as the sole provider of an FSP relationship within their pharmacovigilance team. FSP relationships are gaining popularity in the industry due to the flexibility in resource allocations and the cost savings they can offer to clients.

“These are great achievements for Chiltern,” commented Linda Christmas, Chiltern Executive Vice President, Resourcing Solutions, “and helps us meet our target to develop strategically aligned relationships with our clients. We are delighted that we have been able to partner with two more leading pharmaceutical companies in two different core functions.”


Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.